Prostate Cancer Clinical Trial
Official title:
Phase III Study of Chemo-hormonal Therapy Versus Hormonal Therapy Alone in Advanced Hormone-naives Prostate Cancer Patients.
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation
therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy,
such as docetaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. It is not yet known whether giving
androgen ablation therapy together with docetaxel is more effective than giving androgen
ablation therapy alone in treating patients with advanced prostate cancer.
PURPOSE: This randomized phase III trial is studying androgen ablation and docetaxel to see
how well they work compared with androgen ablation alone in treating patients with advanced
prostate cancer.
OBJECTIVES:
Primary
- Compare the 2-year progression-free survival rate (biological progression and/or
clinical progression) in patients with advanced prostate cancer treated with androgen
ablation with vs without docetaxel.
Secondary
- Compare the overall survival of patients treated with these regimens.
- Compare the time to treatment failure in patients treated with these regimens.
- Compare the toxicity profiles of these regimens in these patients.
- Compare the PSA response rate in patients treated with these regimens.
- Compare the response rate in patients with measurable disease treated with these
regimens.
- Compare the percentage of patients who undergo PSA normalization.
- Compare the quality of life of patients treated with these regimens.
- Compare the efficacy of these regimens in controlling bone pain in these patients.
- Compare the changes in chromogranin A levels in patients treated with these regimens.
- Compare the total cost of care of patients treated with these regimens.
OUTLINE: This is a multicenter study.
Patients receive luteinizing hormone-releasing hormone analogue (LHRH-A) therapy for 6
months. Patients also receive antiandrogen therapy during the first 5 weeks of LHRH-A
therapy. After 6 months of LHRH-A therapy, patients with PSA response are randomized to 1 of
2 treatment arms.
- Arm I: Patients continue to receive LHRH-A therapy until disease progression.
- Arm II:Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV
on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the
absence of disease progression or unacceptable toxicity.
Patients complete questionnaires during treatment to assess bone pain. Quality of life is
also assessed.
After completion to study therapy, patients are followed for ≥ 2 years.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |